Proto-Oncogene Proteins c-kit
"Proto-Oncogene Proteins c-kit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
| Descriptor ID |
D019009
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.050 D12.776.543.750.630.124 D12.776.543.750.705.852.150.100 D12.776.543.750.750.400.200.170 D12.776.624.664.700.183
|
| Concept/Terms |
Proto-Oncogene Proteins c-kit- Proto-Oncogene Proteins c-kit
- Proto Oncogene Proteins c kit
- c-kit, Proto-Oncogene Proteins
- Stem Cell Factor Receptor
- SCF Receptor
- p145 c-kit
- c-kit, p145
- p145 c kit
- p145(c-kit)
- p145c-kit
- p145c kit
- CD117 Antigen
- Antigens, CD117
- CD117 Antigens
- Proto-Oncogene Protein c-kit
- Proto Oncogene Protein c kit
- c-kit, Proto-Oncogene Protein
- c-kit Protein
- c kit Protein
- kit Proto-Oncogene Protein
- Proto-Oncogene Protein, kit
- kit Proto Oncogene Protein
- Receptor, Stem Cell Factor
- Proto-Oncogene Protein kit
- Proto Oncogene Protein kit
- c-kit Receptor
- c kit Receptor
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-kit".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-kit".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-kit" by people in this website by year, and whether "Proto-Oncogene Proteins c-kit" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 4 | 4 | 8 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 0 | 5 | 5 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 5 | 5 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 4 | 1 | 5 |
| 2015 | 3 | 1 | 4 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-kit" by people in Profiles.
-
KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol. 2017 Nov; 177(5):1376-1384.
-
Perivascular Mast Cells Govern Shear Stress-Induced Arteriogenesis by Orchestrating Leukocyte Function. Cell Rep. 2016 08 23; 16(8):2197-2207.
-
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
-
Resident c-kit(+) cells in the heart are not cardiac stem cells. Nat Commun. 2015 Oct 30; 6:8701.
-
Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol. 2015 Apr; 143(4):527-34.
-
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
-
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
-
Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2014 Dec; 156(6):1504-10; discussion 1510-1.
-
DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1. Oncogene. 2015 May 21; 34(21):2741-52.
-
E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol. 2014 May; 141(5):656-64.